Welcome to our dedicated page for Cellectar Biosciences SEC filings (Ticker: CLRB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Cellectar Biosciences's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Cellectar Biosciences's regulatory disclosures and financial reporting.
Kolean Chad J reported acquisition or exercise transactions in this Form 4 filing.
Cellectar Biosciences CFO Chad J. Kolean received a grant of 92,000 stock options to buy common shares at $3.14 per share. The options were contingently granted on May 28, 2026, under Cellectar's amended 2021 Stock Incentive Plan and became effective after stockholders approved the plan on July 7, 2026.
The award vests over three years from May 28, 2026, with one-third vesting on the first anniversary and the remaining two-thirds vesting in 24 equal monthly installments thereafter. Following this grant, Kolean holds 92,000 stock options directly under this award.
Cellectar Biosciences director Frederick W. Driscoll received a grant of stock options representing 25,000 shares of common stock. The options have an exercise price of $2.70 per share and expire on July 7, 2036. They vest in full on July 7, 2027, subject to his continued service, and this grant brings his reported option holdings from this award to 25,000 derivative securities.
Cellectar Biosciences director Asher Chanan-Khan received a grant of stock options covering 25,000 shares of common stock. The options have an exercise price of $2.70 per share and expire on July 7, 2036. According to the terms, the entire grant will vest on July 7, 2027, provided he continues to serve through that date. Following this grant, his reported holdings include 25,000 stock options directly.
Cellectar Biosciences President & CEO James V. Caruso received a grant of stock options to acquire 250,000 shares of common stock at an exercise price of $3.14 per share. These options were contingently granted on May 28, 2026, subject to stockholder approval of the amended 2021 Stock Incentive Plan.
Stockholders approved the amended plan at Cellectar’s 2026 Annual Meeting of Stockholders on July 7, 2026, activating the grant. The options expire on May 28, 2036 and vest over three years, with one-third vesting on May 28, 2027 and the remainder vesting in 24 equal monthly installments thereafter.
Cellectar Biosciences director Andrew Gu received a grant of stock options as equity compensation. On July 7, 2026, he was awarded options covering 25,000 shares of common stock with an exercise price of $2.70 per share and an expiration date of July 7, 2036. According to the footnote, the option vests in full on July 7, 2027, provided he continues to serve the company through that date.
Cellectar Biosciences Chief Operating Officer Jarrod Longcor received a grant of stock options as equity compensation. The award covers 118,000 shares of common stock at an exercise price of $3.14 per share and expires on May 28, 2036.
The option was contingently granted on May 28, 2026 and became effective after stockholders approved the amended 2021 Stock Incentive Plan on July 7, 2026. It vests over three years, with one-third vesting on the first anniversary of May 28, 2026 and the remaining two-thirds vesting in 24 equal monthly installments thereafter.
Cellectar Biosciences director Douglas J. Swirsky received a grant of stock options covering 37,500 shares of common stock at an exercise price of $2.70 per share. The option vests in full on July 7, 2027, subject to his continued service, and expires on July 7, 2036. This is a compensation grant, with no open-market share purchases or sales reported.
Cellectar Biosciences director John Neis received a grant of stock options covering 25,000 shares of common stock. The options were awarded at an exercise price of $2.70 per share and expire on July 7, 2036. Following this grant, he holds options for 25,000 shares.
According to the footnote, the option vests in full on July 7, 2027, subject to his continued service through that vesting date. This is a compensation-related award rather than an open-market purchase or sale.
Cellectar Biosciences, Inc. reported that consultant Loren Stefan received a grant of stock options. The award covers 15,000 stock options with an exercise price of $2.6800 per share, expiring on July 8, 2036. These options relate to 15,000 shares of common stock and will vest in full on July 8, 2027, subject to continued service. Following this grant, Stefan holds 15,000 derivative securities directly.
Cellectar Biosciences, Inc. director Andrew Gu filed an initial Form 3, which is a required statement of beneficial ownership when someone becomes an insider. This filing lists his status as a director but shows no reported purchases, sales, or other transactions in Cellectar securities.